epidermal growth factor receptor inhibitor

上皮成長因子受容体阻害薬

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 上皮成長因子受容体変異を有する進行非小細胞肺癌に対する全身療法systemic therapy for advanced non small cell lung cancer with an activating mutation in the epidermal growth factor receptor [show details]
  … utility of this agent may be further limited by the anticipated transition of third-generation EGFR TKI osimertinib into the first-line setting in the wake of the reported results of the FLAURA trial. Surgery …
• 2. 上皮成長因子受容体（EGFR）阻害薬およびMEK阻害薬の投与に続発するざ瘡様発疹acneiform eruption secondary to epidermal growth factor receptor egfr and mek inhibitors [show details]
  …small-molecule tyrosine kinase inhibitors (eg, gefitinib, erlotinib, afatinib, osimertinib, lapatinib) . The ability of EGFR inhibitors to block specific molecular pathways driving uncontrolled cellular division …
• 3. 血管新生阻害剤の概要overview of angiogenesis inhibitors [show details]
  …drugs (IMiDs); HIF, DLL4, and Tie2/angiopoietin inhibition; epidermal growth factor receptor (EGFR) inhibitors; and vascular targeting agents. Antiangiogenic agents have a variety of cardiovascular and…
• 4. 癌治療に用いる分子標的薬やそれ以外の生物学的製剤により皮膚に生じる有害事象cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy [show details]
  …paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) . Bullous and exfoliative eruptions, including cases suggestive of Stevens-Johnson …
• 5. 分子標的薬である血管新生阻害剤の毒性：心血管系以外への影響toxicity of molecularly targeted antiangiogenic agents non cardiovascular effects [show details]
  …4) in 3 to 17 percent . Vandetanib is a moderately potent epidermal growth factor receptor (EGFR) inhibitor in addition to being a vascular endothelial growth factor receptor (VEGFR) inhibitor, which explains …

English Journal

• Design, synthesis and biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment.

• Le Y, Gan Y, Fu Y, Liu J, Li W, Zou X, Zhou Z, Wang Z, Ouyang G, Yan L.
• Journal of enzyme inhibition and medicinal chemistry. 2020 Dec;35(1)555-564.
• In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity on wild type epidermal growth factor receptor tyrosine kinase (EGFR-TK) and three human cancer cell lines including A549, PC-3, and SMMC-7721. The results displayed tha
• PMID 31967481

• Gefitinib modulates stress fibers and tubular-like structure formation and attenuates angiogenesis in an in vivo chicken model of chorioallantoic membrane angiogenesis.

• , L L, T T, T T, .
• Biochemical and biophysical research communications. 2020 Jun;526(3)568-573.
• Gefitinib is an ATP-competitive inhibitor of receptor tyrosine kinases known to repress the progression of various types of cancers. Emerging evidence has shown that this molecule modulates endothelial cells to inhibit angiogenesis. However, the biological effects of gefitinib have not been comprehe
• PMID 32247613

• Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.

• Dees S, Pontiggia L, Jasmin JF, Mercier I.
• Cancer biology & therapy. 2020 Jun;21(6)506-521.
• Triple-negative breast cancer (TNBC) displays an aggressive clinical course, heightened metastatic potential, and is linked to poor survival rates. Through its lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), this subt
• PMID 32164483

Japanese Journal

• 培養肺胞上皮細胞でのIL-1βによる上皮成長因子受容体の制御機構

• 山本 秀幸,中山 泉,比嘉ー仲嶺 三代美
• 日本薬理学会年会要旨集 93(0), 1-P-104, 2020
• … In the present study, we found that treatment of A549 cells with interleukin 1 beta (IL-1β) induced the activation of p38 mitogen-activated protein kinase (MAP kinase) and MAP kinase-activated protein kinase-2 (MAPKAPK-2), and the phosphorylation of epidermal growth factor receptor (EGFR) at serine 1047. … The activation of MAPKAPK-2 and phosphorylation of EGFR were inhibited by SB203580, an inhibitor of p38 MAP kinase. …
• NAID 130007811349

• 初代培養肝実質細胞に対するセロトニン5-HT_2B受容体作動薬の増殖促進作用はEGF／TGF-α受容体チロシンキナーゼとp70 S6キナーゼのリン酸化を介している

• 栗原 一樹,茂木 肇,荻原 政彦,木村 光利
• 日本薬理学会年会要旨集 93(0), 1-P-101, 2020
• … <p>Serotonin (5-HT) can induce hepatocyte DNA synthesis and proliferation by autocrine secretion of transforming growth factor (TGF)-α through 5-HT_2B … receptor/phospholipase C (PLC)/Ca²⁺. …
• NAID 130007811348

• Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer

• Haruna Miya,Hirata Michinari,Iwahori Kota,Kanazawa Takayuki,Yamamoto Yoko,Goto Kumiko,Kawashima Atsunari,Morimoto-Okazawa Akiko,Funaki Soichiro,Shintani Yasushi,Kumanogoh Atsushi,Wada Hisashi
• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 43(3), 399-403, 2020
• … To identify preferable chemotherapy to combine with ICIs against lung cancer, we examined immunological effects of docetaxel compared with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). …
• NAID 130007804428

Related Links

• List of EGFR inhibitors (anti-EGFR) - Drugs.com

Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it.

• Dermatological Side Effects of Epidermal Growth Factor ...

Epidermal growth factor receptor (EGFR) inhibitor therapy has become the standard treatment for non-small cell lung cancer and head neck malignancy. This class of drug comprises EGFR inhibitors (erlotinib and gefitinib) and monoclonal antibody (cetuximab). ...

• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ...

Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.Results The discovery of EGFR mutations has altered the ways in which we consider and treat non–small-cell lung cancer (NSCLC). ...

---

★リンクテーブル★

リンク元	「上皮成長因子受容体阻害薬」
関連記事	「inhibit」「grow」「inhibitor」「fact」「factor」

「上皮成長因子受容体阻害薬」

　　[★]

英

epidermal growth factor receptor inhibitor

関

上皮成長因子受容体

薬理学

• EGF受容体拮抗薬

• gefitinib, エルロチニブ erlotinib
• セツキシマブ cetuximab,トラスツズマブ trastuzumab

• BCR-ALB/C-KIT/PDGFR阻害薬

• imatinib
• dasatinib, nilotinib

• FLT3阻害薬

• PKC412(midostaurin)

• JAK2阻害薬
• RAS/MAPキナーゼ経路阻害

• tipifarnib
• lonafarnib
• sorafenib

• mTOR阻害薬

• rapamycin(sirolimus)
• temsirolimus(CCI-779)
• everolimus(RAD001)

「inhibit」

　　[★]

• v.

• 抑制する、阻害する、阻止する

関

abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression

　 　 　 　

「grow」

　　[★]

• v.

(過去: grew-過去分詞: grown)

• 成長する、生育する、伸びる

関

extend、growth、outgrow、outgrowth、stretch

　 　 　 　 　 　 　

「inhibitor」

　　[★]

• n.

• 阻害剤、阻害薬、抑制薬、抑制剤、(内在性物質について)インヒビター、抑制物質

関

blocker、depressant、suppressant

　 　

「fact」

　　[★]

• n.

• 事実、現状、実際、実態

関

actual、actually、in fact、in practice、indeed、practically

　 　 　 　 　

「factor」

　　[★]

• n.

• 因子、要因、要素、ファクター

関

element、elementary、factorial、parameter